Literature DB >> 21283099

Tesamorelin.

Carl Grunfeld, Argyris Dritselis, Peter Kirkpatrick.   

Abstract

In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21283099     DOI： 10.1038/nrd3362

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  16 in total

1.  Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy.

Authors:  Carl Grunfeld; Michael Saag; Joseph Cofrancesco; Cora Elizabeth Lewis; Richard Kronmal; Steven Heymsfield; Phyllis C Tien; Peter Bacchetti; Michael Shlipak; Rebecca Scherzer
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

2.  Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors.

Authors:  Carl Grunfeld; Donald P Kotler; Donna K Arnett; Julian M Falutz; Steven M Haffner; Paul Hruz; Henry Masur; James B Meigs; Kathleen Mulligan; Peter Reiss; Katherine Samaras
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

3.  Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.

Authors:  P Rietschel; C Hadigan; C Corcoran; T Stanley; G Neubauer; J Gertner; S Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

4.  Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.

Authors:  Eckhardt S Ferdinandi; Paul Brazeau; Kim High; Bryan Procter; Stephen Fennell; Pascal Dubreuil
Journal:  Basic Clin Pharmacol Toxicol       Date:  2007-01       Impact factor: 4.080

5.  Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Authors:  Julian Falutz; Jean-Claude Mamputu; Diane Potvin; Graeme Moyle; Graziella Soulban; Helen Loughrey; Christian Marsolais; Ralph Turner; Steven Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2010-06-16       Impact factor: 5.958

6.  A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding.

Authors:  A Thörne; F Lönnqvist; J Apelman; G Hellers; P Arner
Journal:  Int J Obes Relat Metab Disord       Date:  2002-02

7.  Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.

Authors:  Polyxeni Koutkia; Bridget Canavan; Jeff Breu; Martin Torriani; John Kissko; Steven Grinspoon
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

Review 8.  Abdominal obesity as important component of insulin-resistance syndrome.

Authors:  J P Després
Journal:  Nutrition       Date:  1993 Sep-Oct       Impact factor: 4.008

9.  Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.

Authors:  Michael J Silverberg; Wendy Leyden; Leo Hurley; Alan S Go; Charles P Quesenberry; Daniel Klein; Michael A Horberg
Journal:  Ann Intern Med       Date:  2009-03-03       Impact factor: 25.391

10.  Metabolic effects of a growth hormone-releasing factor in patients with HIV.

Authors:  Julian Falutz; Soraya Allas; Koenraad Blot; Diane Potvin; Donald Kotler; Michael Somero; Daniel Berger; Stephen Brown; Gary Richmond; Jeffrey Fessel; Ralph Turner; Steven Grinspoon
Journal:  N Engl J Med       Date:  2007-12-06       Impact factor: 91.245
View more
  3 in total

Review 1.  Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.

Authors:  Phyllis C Tien
Journal:  Curr Atheroscler Rep       Date:  2015-12       Impact factor: 5.113

Review 2.  An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  François Maltais; Marc Decramer; Richard Casaburi; Esther Barreiro; Yan Burelle; Richard Debigaré; P N Richard Dekhuijzen; Frits Franssen; Ghislaine Gayan-Ramirez; Joaquim Gea; Harry R Gosker; Rik Gosselink; Maurice Hayot; Sabah N A Hussain; Wim Janssens; Micheal I Polkey; Josep Roca; Didier Saey; Annemie M W J Schols; Martijn A Spruit; Michael Steiner; Tanja Taivassalo; Thierry Troosters; Ioannis Vogiatzis; Peter D Wagner
Journal:  Am J Respir Crit Care Med       Date:  2014-05-01       Impact factor: 21.405

Review 3.  Therapeutic peptides: current applications and future directions.

Authors:  Lei Wang; Nanxi Wang; Wenping Zhang; Xurui Cheng; Zhibin Yan; Gang Shao; Xi Wang; Rui Wang; Caiyun Fu
Journal:  Signal Transduct Target Ther       Date:  2022-02-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.